Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-825-4 | CAS number: 378-44-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2009
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP, non-guideline study but otherwise adequate for assessment.
Data source
Reference
- Reference Type:
- publication
- Title:
- Semen parameters, fertility and testosterone levels in male rats exposed prenatally to betamethasone
- Author:
- Piffer, R.C.; Garcia, P.C.; Gerardin, D.C.; Kempinas, W.G.; Pereira, O.C.
- Year:
- 2 009
- Bibliographic source:
- Reprod. Fertil. Dev. 2009, 21, 634-639.
Materials and methods
- Principles of method if other than guideline:
- Betamethasone 21-phosphate was injected to pregnant rats on day 12, 13, 28, and 19. the betamethasone treatment corresponds to theraphy used in pregnant woman. Days 12 and 13 were selected as during organogenesis of fetuses. Days 18 and 19 coincide with the time of greater vulnerability because of testosterone peak of producion.
Sperm quality and count of the offspring in their adulthood (Postnatal Day 90) were examined. At the same time plasma concentration of testosterone and fertility were evaluated. - GLP compliance:
- not specified
Test material
- Reference substance name:
- Betamethasone 21-phosphate
- IUPAC Name:
- Betamethasone 21-phosphate
- Reference substance name:
- Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (11β,16β)-
- EC Number:
- 205-797-0
- EC Name:
- Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (11β,16β)-
- Cas Number:
- 151-73-5
- IUPAC Name:
- Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (11beta,16beta)-
- Details on test material:
- - Name of test material (as cited in study report): Betamethasone 21-phosphate disodium
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Multidisciplinary Center for Biological Investigation, State University of Campinas, Brazil
- Age at study initiation: 90 days old
- Weight at study initiation: 230 ± 10 g
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 25 ± 1°C
- Humidity (%): 55 ± 5%
- Photoperiod (hrs dark / hrs light): light fropm 06.00 to 18.00
Administration / exposure
- Route of administration:
- intramuscular
- Vehicle:
- physiological saline
- Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused: mated with one fertile untreated male of the same age
- M/F ratio per cage: 1/1
- Length of cohabitation: till the morning on which spermatozoa were found in the smear
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 1 of pregnancy - Duration of treatment / exposure:
- Betamethasone was injected in four days of pregnancy: day 12, 13, 18, and 19
- Frequency of treatment:
- Daily
- Duration of test:
- The offspring was analyzed till day 90 of life (adulthood)
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.1 mg/kg betamethasone diluted in sterile physiological solution
Basis:
nominal conc.
- No. of animals per sex per dose:
- 8 female rats
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The betamethasone treatment corresponds to therapy used in pregnant woman, and the treatment period was selected based on the corticosteroid therapy administered to women at risk of premature delivery. Thus, was started at the end of the first half of pregnancy and the second course of treatment, on day 18 and 19, was administered during the period of brain sexual differentiation.
- Rationale for animal assignment (if not random): random assigned
Examinations
- Statistics:
- Student's t-test, the Mann-Whitney U-test and Fisher's exact test were used, with results considered significant at P<0.05.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Effect levels (maternal animals)
- Dose descriptor:
- dose level:
- Effect level:
- 0.1 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
Prenatal treatment with betamethasone may result in decreased endogenous levels of testosteronein male pups, which are crucial for brain sexual differentiation, with conseguent drop of testosterone production in adulthood, in association with damaged semen parameters.
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Only relevant data is reported.
Control | Betamethasone-treated | |
Sperm concentration (x 106) | 77.8 ± 5.6 | 57.0 ± 4.4 (p<0.01 Student's t-test) |
Motility (%) | 67 (59 -75) | 61 (38 -64) (p<0.05) |
No. spermatidis (x106 per testis) | 241 ± 6 | 197 ± 4 (p<0.001 Student's t-test) |
Testosterone level (ng dL-1) | 393 ±53 | 187 ± 19 (p<0.05 t-test with Welch correction) |
Testis weight (g) | 1.60 ± 0.03 | 1.48 ± 0.04 (p<0.05 Student's t-test) |
Rates of implantation, pre- and post-implantation losses and fetal viability in pregnant female rats mated with male control rats and males exposed prenatally to betamethasone
Control (n=10) | Betamethasone-treated (n=8) | |
Implantation (%) | 100 (93 -100) | 87 (61 -89) (p<0.05 Mann-Whitney U-test) |
Post-implantation loss (%) | 8 (8 -11) | 31 (25 -43) (p<0.05 Mann-Whitney U-test) |
Fetal viability (%) | 100 (97 -100) | 75 (61 -89) (p<0.05 Mann-Whitney U-test) |
Applicant's summary and conclusion
- Conclusions:
- Prenatal treatment with betamethasone led to significant reduction in sperm concentration and spermatid number.
In adult male rats, prenatal exposure to betamethasone led to a significant reduction in plasma testosterone concentration. Derease of testosterone production led to long term effects on fertility of adult male rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.